Combination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism
. Furthermore, combining these two metabolic inhibitors could induce the production of ROS, reduce the generation of ATP, impair mitochondrial morphology and function, and ultimately activate apoptosis in tumor cells through metabolic regulation, facilitating antitumor treatment. The findings underscore the necessity and effectiveness of targeting tumor energy metabolism for lung cancer therapy, providing reliable evidence that metabolic therapies can effectively participate in cancer treatment.
Authors
- Qingze Fan (ORCID: https://orcid.org/0000-0002-3212-0002)
- Yan Dai (ORCID: https://orcid.org/0000-0001-5890-8087)
- Meiling Zhou (ORCID: https://orcid.org/0000-0002-0559-2450)
- Yaqin Zou
- Xiao Han (ORCID: https://orcid.org/0000-0002-6467-1802)
- Xuping Yang (ORCID: https://orcid.org/0000-0002-8611-1726)
- Yongfeng Yang (ORCID: https://orcid.org/0000-0003-1642-6631)
- Shiwei Guo (ORCID: https://orcid.org/0000-0003-1020-0236)
- Pei Jing
- Xinhe Bai
- Yuling Luo (ORCID: https://orcid.org/0009-0002-2826-4780)
- Xia Hong (ORCID: https://orcid.org/0009-0006-1294-9346)
- Yilan Huang
Institutions
- Affiliated Hospital of Southwest Medical University (CN)
Publication Details
- Journal
- Oncology Reports
- Published
- 2026-08-20
- DOI
- https://doi.org/10.3892/or.2026.9184
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00